New Therapeutic Approach for Spinal Cord Injuries
Author: Elsevier Health Sciences
Published: 2012-03-14 : (Rev. 2016-03-19)
Research suggests a possible new avenue to counteract the degeneration of the spinal cord in human SCI.
Research suggests new therapeutic approach for spinal cord injury - Results reported in the American Journal of Pathology.
Spinal cord trauma is damage to the spinal cord. It may result from direct injury to the cord itself or indirectly from damage to surrounding bones, tissues, or blood vessels. Symptoms vary somewhat depending on the location of the injury. Spinal cord injury causes weakness and sensory loss at and below the point of the injury. The severity of symptoms depends on whether the entire cord is severely injured (complete) or only partially injured (incomplete).
A new study suggests that administering FTY720, an oral drug that has shown promise in trials for human multiple sclerosis, significantly improves locomotor recovery in mice with spinal cord injury (SCI). The research suggests a possible new avenue to counteract the degeneration of the spinal cord in human SCI. The study will be published in the April 2012 issue of The American Journal of Pathology.
Beyond the initial tissue damage, much of the degradation of the spinal cord in SCI is due to a cascade of secondary injuries, including neuronal and glial apoptosis, inflammation, glial scar formation, local edema and ischemia, and oxidative stress. The aim of current SCI treatment is to counteract the mechanisms of secondary injury and prevent their pathological consequences, because central nervous system (CNS) neurons have very limited capacity to self-repair and regenerate.
Researchers from the Jichi Medical University School of Medicine and the Graduate School of Medicine at the University of Tokyo had previously shown that the concentration of the lysophospholipid mediator, sphingosine 1-phosphate (S1P), was significantly increased in the location of a contusion injury, triggering the migration of neural progenitor/stem cells to the site of the injury. They hypothesized that targeting S1P receptors may become a candidate therapy for various refractory central nervous system disorders, including SCI.
FTY720 acts as a broad S1P receptor modulator.
Its efficacy in central nervous system disorders is believed to derive from immunomodulation. Researchers found that orally administering FTY720 to mice shortly after contusion SCI significantly improved motor function recovery. Importantly, they found that the therapeutic effects of FTY720 were not solely dependent on immune modulation. The administration of FTY720 induced lymphopenia, clearing lymphocytes from the blood, and reduced T-cell infiltration in the spinal cord. But it did not affect the early infiltration of neutrophils and activation of microglia, and it did not reduce plasma levels and mRNA expression of inflammatory cytokines in the spinal cord. Tests in mice with severe combined immunodeficiency (SCID mice) with SCI found that FTY720 significantly improved recovery of hind limb motor function.
"These data clearly indicate the importance of immune-independent functions of FTY720 in the amelioration of functional deficits after SCI in mice," explains lead investigator Yoichi Sakata, MD, PhD, Research Division of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical University School of Medicine.
Dr. Sakata notes that S1P receptors exist in many types of cells and play a role in many cellular processes.
"We observed that FTY720 decreased vascular permeability and astrocyte accumulation in injured spinal cord. These changes were also noted in SCID mice, suggesting they are not dependent on lymphocyte function. Increased vascular permeability can lead to destruction of the blood-brain barrier in spinal cord, and astrocyte accumulation is the main cellular component of glial scar after CNS injury. FTY720 might counteract these secondary injuries and thereby prevent their pathological consequences."
"Our data suggest that targeting S1P receptors with FTY720 is an attractive therapeutic approach for SCI," Dr. Sakata concludes. "However, further evaluation utilizing larger animals such as non-human primates will be necessary to confirm its efficacy in treating SCI. Further, strategies targeted at modulating the SIP concentration in injured CNS may lead to new therapeutic approaches towards repairing various CNS disorders."
- 1 - Cell Pores Discovery: Hope for Millions of Brain and Spinal Cord Injury Patients : Aston University (2020/05/17)
- 2 - Human Spine and Spinal Cord Picture C1 - S5 Vertebra : Disabled World (2017/12/01)
- 3 - Working Around Spinal Injuries - Spinal Cord Functional Recovery : University of California - Davis (2017/07/26)
- 4 - Cervical Hernias Can Cause Brain Damage Research Reveals : Network of Valencian Universities for the promotion of Research (2020/01/17)
- 5 - Reflex Control Could Improve Walking after Incomplete Spinal Injuries : National Institutes of Health (NIH) (2013/03/10)
- 6 - Spinal Cord Neural Stem Cells Show Diverse Promise for SCI : University of California - San Diego (2018/08/14)
- 7 - Majority of Patients with Unknown Spinal Cord Disease Later Given Specific Diagnosis : Mayo Clinic (2018/01/09)
• Disabled World is strictly a news and information website provided for general informational purpose only and does not constitute medical advice. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World.
• Please report outdated or inaccurate information to us.